Chugai Pharmaceutical Co., Ltd.
4519
주식 순위
#358
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
주가
$41.17
시가총액
$67.75B
변동 (1일)
-0.68%
변동 (1년)
-15.27%
국가
JP
거래 Chugai Pharmaceutical Co., Ltd. (4519)
카테고리
Healthcare
Chugai Pharmaceutical Co., Ltd. (4519)의 배당 수익률 기록
Chugai Pharmaceutical Co., Ltd. (주식 심볼: 4519)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
지난 5년 평균 배당 수익률: 0.00%
Chugai Pharmaceutical Co., Ltd. (4519)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
| 연도 | 배당 수익률 | 변화 |
|---|---|---|
| 제공된 날짜에 대한 데이터가 충분하지 않습니다. | ||
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
| 회사 | 배당 수익률 | 국가 |
|---|---|---|
| 0.55% |
US
|
|
| 2.08% |
US
|
|
| 2.44% |
US
|
|
| 2.31% |
US
|
|
| 2.69% |
CH
|
